Topic: A2AR

Derived from the unique immune system of camelids, nanobodies are compact single-domainantibodies that have revolutionized the field of biomedical research. These miniaturized antibodies offer numerous advantages, including high specificity, stability, and ease of engineering. Interestingly, A2AR and mGlu5R form heteromers in the striatum, exhibiting synergistic transinhibition over striatal D2R signaling. 1 This oligomerization provides a unique pharmacological opportunity to explore whether the physical proximity of these receptors enables oligomer-dependent orthogonal targeting of counterpa

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to reduced striatal dopamine and motor and non-motor symptoms. The imbalance of adenosine signaling plays a role in the pathogenesis of PD, particularly through increased A2AR and reduced A1R activity affecting D2R and D1R signaling pathways, respectively. This imbalance interferes with the reciprocal modulation of adenylate cyclase by A1R/D1R and A2AR/D2R and impairs motor control. Despite existing treatment options, there is an unmet need for new interve